Project Grant DP2DA056130
Award Date
4/15/22
Completion Date
3/31/26
Dollars Obligated
$4.9M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This $196,350 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University. The grant will fund a project titled "HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES" from August 1, 2024 to July 31, 2026. The project aims to elucidate the causal relationship between drug use disorders, HIV acquisition, gut microbiome, and immune responses using Mendelian randomization...
This $1,210,300 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel polyvalent HIV vaccines designed to prevent intravenous transmission in people who inject drugs (PWID). The research team at Beth Israel Deaconess Medical Center, Inc. (BIDMC) will create diverse HIV envelope-based vaccines and evaluate their ability to rapidly clear multiple viral strains in animal models, with...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $181,974 over 5 years to The Johns Hopkins University to conduct implementation science research optimizing HIV prevention and harm reduction services for men who have sex with men engaged in transactional sex in Baltimore, Maryland. The award will fund training and mentored research for the principal investigator, Dr. Atkins, to...
This Project Grant award of $1,422,136 from the National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Yale University aims to develop and evaluate novel methods to predict, detect, and diagnose outbreaks of HIV and other infectious diseases among people who use drugs. The key products and services to be delivered under this 5-year grant include: Developing modeling and pattern-recognition frameworks to predict jurisdictions at high risk of incipient infectious disease...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $234,000.00 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids such as fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, as well as to longitudinally measure and...
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop effective methods for disseminating scientific evidence to policymakers in order to improve access to services that can prevent HIV transmission and overdose among people who use drugs. The $2,362,500 award, effective July 1, 2025 through June 30, 2029, will be administered by the University of California, Los Angeles...